메뉴 건너뛰기




Volumn 116, Issue 4, 2010, Pages 537-543

The effect of deferasirox on cardiac iron in thalassemia major: Impact of total body iron stores

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; FERRITIN; IRON; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

EID: 77953779950     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-11-250308     Document Type: Article
Times cited : (129)

References (38)
  • 2
    • 0030048681 scopus 로고    scopus 로고
    • Results of long-term iron-chelating therapy
    • Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95(1):26-36.
    • (1996) Acta Haematol , vol.95 , Issue.1 , pp. 26-36
    • Gabutti, V.1    Piga, A.2
  • 3
    • 0034631379 scopus 로고    scopus 로고
    • Survival in beta-thalassaemia major in the UK: Data from the UK Thalassaemia Register
    • Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355(9220):2051-2052.
    • (2000) Lancet , vol.355 , Issue.9220 , pp. 2051-2052
    • Modell, B.1    Khan, M.2    Darlison, M.3
  • 4
    • 0028059813 scopus 로고
    • Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major
    • Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567-573.
    • (1994) N Engl J Med , vol.331 , Issue.9 , pp. 567-573
    • Brittenham, G.M.1    Griffith, P.M.2    Nienhuis, A.W.3
  • 5
    • 34247271478 scopus 로고    scopus 로고
    • Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective
    • DOI 10.2165/00019053-200725040-00005
    • Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Pharmacoeconomics. 2007;25(4):329-342. (Pubitemid 46607383)
    • (2007) PharmacoEconomics , vol.25 , Issue.4 , pp. 329-342
    • Delea, T.E.1    Sofrygin, O.2    Thomas, S.K.3    Baladi, J.-F.4    Phatak, P.D.5    Coates, T.D.6
  • 6
    • 34547824328 scopus 로고    scopus 로고
    • Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia
    • Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29(5):909-917.
    • (2007) Clin Ther , vol.29 , Issue.5 , pp. 909-917
    • Cappellini, M.D.1    Bejaoui, M.2    Agaoglu, L.3
  • 7
    • 52249085605 scopus 로고    scopus 로고
    • Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload
    • Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9(13):2391-2402.
    • (2008) Expert Opin Pharmacother , vol.9 , Issue.13 , pp. 2391-2402
    • Cappellini, M.D.1    Taher, A.2
  • 8
    • 60749134100 scopus 로고    scopus 로고
    • Deferasirox in MDS patients with transfusion-caused iron overload: A phase-II study
    • Metzgeroth G, Dinter D, Schultheis B, et al. Deferasirox in MDS patients with transfusion-caused iron overload: a phase-II study. Ann Hematol. 2009;88(4):301-310.
    • (2009) Ann Hematol , vol.88 , Issue.4 , pp. 301-310
    • Metzgeroth, G.1    Dinter, D.2    Schultheis, B.3
  • 9
    • 33749991316 scopus 로고    scopus 로고
    • Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major
    • Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica. 2006;91(10):1343-1351.
    • (2006) Haematologica , vol.91 , Issue.10 , pp. 1343-1351
    • Galanello, R.1    Piga, A.2    Forni, G.L.3
  • 10
    • 38049151217 scopus 로고    scopus 로고
    • Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study
    • Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80(2):168-176.
    • (2008) Eur J Haematol , vol.80 , Issue.2 , pp. 168-176
    • Porter, J.1    Galanello, R.2    Saglio, G.3
  • 11
    • 33846012866 scopus 로고    scopus 로고
    • A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease
    • Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136(3):501-508.
    • (2007) Br J Haematol , vol.136 , Issue.3 , pp. 501-508
    • Vichinsky, E.1    Onyekwere, O.2    Porter, J.3
  • 12
    • 46049087344 scopus 로고    scopus 로고
    • Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: Substudy of a randomized open-label phase II trial
    • Vichinsky E, Pakbaz Z, Onyekwere O, et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis: substudy of a randomized open-label phase II trial. Acta Haematol. 2008;119(3):133-141.
    • (2008) Acta Haematol , vol.119 , Issue.3 , pp. 133-141
    • Vichinsky, E.1    Pakbaz, Z.2    Onyekwere, O.3
  • 13
    • 73149085204 scopus 로고    scopus 로고
    • Satisfaction and adherence significantly improves in beta-thalassemia and myelodysplastic syndromes treated with deferasirox (Exjade)
    • abstract
    • Porter JB, Bowden D, Ganser A, et al. Satisfaction and adherence significantly improves in beta-thalassemia and myelodysplastic syndromes treated with deferasirox (Exjade) [abstract]. Blood. 2008;112(11):1306.
    • (2008) Blood , vol.112 , Issue.11 , pp. 1306
    • Porter, J.B.1    Bowden, D.2    Ganser, A.3
  • 14
    • 33745774771 scopus 로고    scopus 로고
    • Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload
    • Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91(7):873-880.
    • (2006) Haematologica , vol.91 , Issue.7 , pp. 873-880
    • Piga, A.1    Galanello, R.2    Forni, G.L.3
  • 15
    • 10744230223 scopus 로고    scopus 로고
    • Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: A randomised, double-blind, placebo-controlled, dose-escalation trial
    • Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361(9369):1597-1602.
    • (2003) Lancet , vol.361 , Issue.9369 , pp. 1597-1602
    • Nisbet-Brown, E.1    Olivieri, N.F.2    Giardina, P.J.3
  • 16
    • 65349110837 scopus 로고    scopus 로고
    • Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia
    • Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia. Eur J Haematol. 2009;82(6):454-457.
    • (2009) Eur J Haematol , vol.82 , Issue.6 , pp. 454-457
    • Daar, S.1    Pathare, A.2    Nick, H.3
  • 17
    • 0029978555 scopus 로고    scopus 로고
    • Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy
    • Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood. 1996;88(2):705-713. (Pubitemid 26240403)
    • (1996) Blood , vol.88 , Issue.2 , pp. 705-713
    • Porter, J.B.1    Abeysinghe, R.D.2    Marshall, L.3    Hider, R.C.4    Singh, S.5
  • 18
    • 27644539382 scopus 로고    scopus 로고
    • Intracellular labile iron pools as direct targets of iron chelators: A fluorescence study of chelator action in living cells
    • Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106(9):3242-3250.
    • (2005) Blood , vol.106 , Issue.9 , pp. 3242-3250
    • Glickstein, H.1    El, R.B.2    Shvartsman, M.3    Cabantchik, Z.I.4
  • 19
    • 33750001927 scopus 로고    scopus 로고
    • Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences
    • Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108(9):3195-3203.
    • (2006) Blood , vol.108 , Issue.9 , pp. 3195-3203
    • Glickstein, H.1    El, R.B.2    Link, G.3
  • 20
    • 34250360747 scopus 로고    scopus 로고
    • Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy
    • Otto-Duessel M, Aguilar M, Nick H, Moats R,Wood JC. Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp Hematol. 2007;35(7):1069-1073.
    • (2007) Exp Hematol , vol.35 , Issue.7 , pp. 1069-1073
    • Otto-Duessel, M.1    Aguilar, M.2    Nick, H.3    Moats, R.4    Wood, J.C.5
  • 22
    • 77649296214 scopus 로고    scopus 로고
    • Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major
    • Pathare A, Taher A, Daar S. Deferasirox (Exjade) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol. 2010;89(4):405-409.
    • (2010) Ann Hematol , vol.89 , Issue.4 , pp. 405-409
    • Pathare, A.1    Taher, A.2    Daar, S.3
  • 23
    • 77950617863 scopus 로고    scopus 로고
    • Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia
    • Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115(12):2364-2371.
    • (2010) Blood , vol.115 , Issue.12 , pp. 2364-2371
    • Pennell, D.J.1    Porter, J.B.2    Cappellini, M.D.3
  • 24
    • 18044399191 scopus 로고    scopus 로고
    • Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload
    • Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22(23):2171-2179.
    • (2001) Eur Heart J , vol.22 , Issue.23 , pp. 2171-2179
    • Anderson, L.J.1    Holden, S.2    Davis, B.3
  • 26
    • 72449177984 scopus 로고    scopus 로고
    • Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major
    • Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation. 2009;120(20):1961-1968.
    • (2009) Circulation , vol.120 , Issue.20 , pp. 1961-1968
    • Kirk, P.1    Roughton, M.2    Porter, J.B.3
  • 27
    • 23744459788 scopus 로고    scopus 로고
    • MRI R2 and R2*mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients
    • DOI 10.1182/blood-2004-10-3982
    • Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-1465. (Pubitemid 41129616)
    • (2005) Blood , vol.106 , Issue.4 , pp. 1460-1465
    • Wood, J.C.1    Enriquez, C.2    Ghugre, N.3    Tyzka, J.M.4    Carson, S.5    Nelson, M.D.6    Coates, T.D.7
  • 28
    • 23044475721 scopus 로고    scopus 로고
    • Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy
    • Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112(4):535-543.
    • (2005) Circulation , vol.112 , Issue.4 , pp. 535-543
    • Wood, J.C.1    Otto-Duessel, M.2    Aguilar, M.3
  • 29
    • 77950425913 scopus 로고    scopus 로고
    • Deferasirox pharmacokinetics in patients with adequate versus inadequate response
    • Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009;114(19):4009-4013.
    • (2009) Blood , vol.114 , Issue.19 , pp. 4009-4013
    • Chirnomas, D.1    Smith, A.L.2    Braunstein, J.3
  • 30
    • 70449403619 scopus 로고    scopus 로고
    • Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
    • Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147(5):752-759.
    • (2009) Br J Haematol , vol.147 , Issue.5 , pp. 752-759
    • Taher, A.1    Cappellini, M.D.2    Vichinsky, E.3
  • 31
    • 65349152022 scopus 로고    scopus 로고
    • Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: The ESCALATOR study
    • Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Eur J Haematol. 2009;82(6):458-465.
    • (2009) Eur J Haematol , vol.82 , Issue.6 , pp. 458-465
    • Taher, A.1    El-Beshlawy, A.2    Elalfy, M.S.3
  • 32
    • 0038481233 scopus 로고    scopus 로고
    • Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: Indication of close relation between myocardial iron content and chelatable iron pool
    • Jensen PD, Jensen FT, Christensen T, Eiskjaer H, Baandrup U, Nielsen JL. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood. 2003;101(11):4632-4639.
    • (2003) Blood , vol.101 , Issue.11 , pp. 4632-4639
    • Jensen, P.D.1    Jensen, F.T.2    Christensen, T.3    Eiskjaer, H.4    Baandrup, U.5    Nielsen, J.L.6
  • 33
    • 0033760134 scopus 로고    scopus 로고
    • Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major
    • Telfer PT, Prestcott E, Holden S,Walker M, Hoffbrand AV,Wonke B. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol. 2000;110(4):971-977.
    • (2000) Br J Haematol , vol.110 , Issue.4 , pp. 971-977
    • Telfer, P.T.1    Prestcott, E.2    Holden, S.3    Walker, M.4    Hoffbrand, A.V.5    Wonke, B.6
  • 34
    • 53449102748 scopus 로고    scopus 로고
    • Longitudinal analysis of heart and liver iron in thalassemia major
    • Noetzli LJ, Carson SM, Nord AS, Coates TD,Wood JC. Longitudinal analysis of heart and liver iron in thalassemia major. Blood. 2008;112(7):2973-2978.
    • (2008) Blood , vol.112 , Issue.7 , pp. 2973-2978
    • Noetzli, L.J.1    Carson, S.M.2    Nord, A.S.3    Coates, T.D.4    Wood, J.C.5
  • 35
    • 74049116227 scopus 로고    scopus 로고
    • Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major
    • Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466-475.
    • (2010) Br J Haematol , vol.148 , Issue.3 , pp. 466-475
    • Farmaki, K.1    Tzoumari, I.2    Pappa, C.3    Chouliaras, G.4    Berdoukas, V.5
  • 36
    • 38349157810 scopus 로고    scopus 로고
    • Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major
    • Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood. 2008;111(2):583-587.
    • (2008) Blood , vol.111 , Issue.2 , pp. 583-587
    • Cohen, A.R.1    Glimm, E.2    Porter, J.B.3
  • 37
    • 33646387405 scopus 로고    scopus 로고
    • Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis
    • Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood. 2006;107(9):3738-3744.
    • (2006) Blood , vol.107 , Issue.9 , pp. 3738-3744
    • Pennell, D.J.1    Berdoukas, V.2    Karagiorga, M.3
  • 38
    • 34247103036 scopus 로고    scopus 로고
    • A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance
    • Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876-1884.
    • (2007) Circulation , vol.115 , Issue.14 , pp. 1876-1884
    • Tanner, M.A.1    Galanello, R.2    Dessi, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.